KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Cash & Equivalents (2020 - 2025)

Organon (OGN) has 6 years of Cash & Equivalents data on record, last reported at $574.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 14.96% year-over-year to $574.0 million; the TTM value through Dec 2025 reached $574.0 million, down 14.96%, while the annual FY2025 figure was $574.0 million, 14.96% down from the prior year.
  • Cash & Equivalents reached $574.0 million in Q4 2025 per OGN's latest filing, down from $672.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.0 billion in Q3 2021 and bottomed at $141.0 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $603.0 million, with a median of $635.5 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: soared 6041.67% in 2021, then tumbled 50.5% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $737.0 million in 2021, then decreased by 4.21% to $706.0 million in 2022, then fell by 1.84% to $693.0 million in 2023, then dropped by 2.6% to $675.0 million in 2024, then decreased by 14.96% to $574.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $574.0 million in Q4 2025, $672.0 million in Q3 2025, and $599.0 million in Q2 2025.